Efficacy of second-line chemotherapy after a first-line triplet in patients with metastatic colorectal cancer.

ABSTRACT:

Background

Exposing patients with metastatic colorectal cancer (mcrc) to all three active chemotherapeutic agents (oxaliplatin, irinotecan, fluorouracil) has improved survival. The benefit of second-line chemotherapy after a first-line triplet is not clearly defined. We evaluated the efficacy of second-line chemotherapy in patients who had received first-line triplet therapy.

Methods

The medical records of patients treated on a prospective trial of first-line triplet therapy were reviewed for second-line treatment. Univariate and multivariate analyses were performed to establish factors of prognostic significance.

Results

Of the 53 patients who received first-line triplet therapy, 28 (53%) received second-line chemotherapy [13 men; 8 with a colon primary; mutant KR

SUBMITTER: Bazarbashi S 

PROVIDER: S-EPMC6380651 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature